In England these drugs have been given to thousands of minors since 2011 but are now proving insufficient
London, Thanasis Gavos
The prevailing worldwide practice of granting the so-called puberty blockers – an entire pharmaceutical industry aimed at enabling minors to change sex – ‘is built on shaky foundations’, finds multi-year survey of English practices NHS.
Puberty blockers are hormonal drugs which delay the physical changes of puberty to allow time for the child to decide its gender identity.
In the NHS in England these drugs have been given to thousands of minors from 2011 onwards, while referrals to the Juvenile Gender Identity Service have increased a hundredfold over the past decade or so.
His report NHS
Dr Hilary Cash, former president of the Royal Society of Paediatrics and Child Health in Britain, was commissioned by the NHS in 2020 to study the services provided to children experiencing gender dysphoria.
In her conclusion she states that the practice of puberty blockers is not based on sufficient medical evidences and does not recommend the holistic approach that should be followed in cases of gender transition.
Dr. Cass suggests moving from the emphasis on drug inhibitors towards a holistic model which will also address the mental health problems that may be faced by children with gender dysphoria the in the process of gender transition.
As she states in her report, for most young people the medication route is not the best way to manage the disruption caused by gender dysmorphia and in this sense children in this process have been ‘betrayed’ by the NHS over the years.
Dr. Kass noted that use of puberty blockers expanded with speed around the world, but at the base of a single study from the Netherlands which started in 1998. He added that it is not even clear whether these hormonal drugs are completely safe for health.
The Cass report is the result of the world’s largest investigation into the issue of medical reassignment services for minors, at a time of intense public debate in the UK. The research involved young people with gender dysphoria, families, academics and doctors.
Among other changes to the way it deals with such incidents, the NHS has decided to ban puberty blockers from being given to children under 16.
British Prime Minister Rishi Sunak welcomed the research’s finding, saying “we simply don’t know the long-term impact of drug treatments or social transition (on children) and we should therefore be very careful.”
Source :Skai
I have worked in the news industry for over 10 years. I have a vast amount of experience in covering health news. I am also an author at News Bulletin 247. I am highly experienced and knowledgeable in this field. I am a hard worker and always deliver quality work. I am a reliable source of information and always provide accurate information.
